Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19009018 | 0.83 | GLS (0.48) | GLSTHRBLMNAHDAC1HDAC6 | |
| SCHEMBL30646537 | 0.82 | GLS (0.45) | GLSTHRBLMNAHDAC1HDAC6 | |
| SCHEMBL2824188 | 0.79 | GLS (0.48) | GLSTHRBLMNAHDAC1HDAC6 | |
| SCHEMBL19000038 | 0.79 | PSMB8 (0.45) | GLSTHRBFDPSMEN1TSHR | |
| SCHEMBL1259469 | 0.77 | ALDH1A1 (0.55) | LMNAMEN1TSHRKMT2AMAPK14 | |
| SCHEMBL2754374 | 0.76 | FOLH1 (0.36) | — | |
| SCHEMBL11971222 | 0.76 | — | — | |
| SCHEMBL28677702 | 0.76 | HPGD (0.51) | LMNATSHR | |
| SCHEMBL24571260 | 0.76 | PSMB8 (0.44) | GLSTHRBLMNAFDPSMEN1 | |
| SCHEMBL9206601 | 0.76 | GLS (0.41) | GLSTHRBLMNAHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | NOCION THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20230107360-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2023-04-06 | — | — | US | disclosed |
| US-11512058-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2022-11-29 | — | — | US | disclosed |
| US-20220274936-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2022-09-01 | — | — | US | disclosed |
| EP-3937945-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-10934263-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10786485-B1 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200289468-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| WO-2020185881-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. (US) | 2020-09-17 | — | — | WO | disclosed |
| US-20200290979-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| WO-2017106607-A1 | POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512058-B2 | Charged ion channel blockers and methods for use | TRPV1, ASIC1, TRPA1 | GLS 2030/4885THRB 1756/4885LMNA 2395/4885 |
| US-10934263-B2 | Charged ion channel blockers and methods for use | TRPV1, ASIC1, TRPA1 | GLS 2030/4885THRB 1756/4885LMNA 2395/4885 |
| US-20200290979-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, ASIC1, TRPA1 | GLS 2030/4885THRB 1756/4885LMNA 2395/4885 |
| US-10786485-B1 | Charged ion channel blockers and methods for use | TRPV1, TRPA1, ASIC1 | GLS 2083/4885THRB 1776/4885LMNA 2416/4885 |
| US-20200289468-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPA1, ASIC1 | GLS 2083/4885THRB 1776/4885LMNA 2416/4885 |
| US-20230107360-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV5, TRPA1 | GLS 2093/4885THRB 1866/4885LMNA 2605/4885 |
| US-20260116859-A1 | Charged Ion Channel Blockers and Methods for Use | OPRL1, TRPV1, SCN2B | GLS 2025/4885THRB 663/4885LMNA 1958/4885 |
| US-20220274936-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, ASIC1, TRPA1 | GLS 2030/4885THRB 1756/4885LMNA 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.